Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Herpes Simplex Virus Infection Clinical Trial

Official title:
A Phase I, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Subcutaneous Dose of UB-621 in Healthy Volunteers

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of a single subcutaneous dose of UB-621 in healthy volunteers.

Clinical Trial Description

This is a phase I, open-label, single dose, dose escalation study in healthy volunteers. Eligible volunteers will be sequentially enrolled into four escalating-dose cohorts at a study site. After administration of a single subcutaneous dose of UB-621, subjects will be followed for 70 or 112 days and monitored for safety, tolerability, and pharmacokinetics parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02346760
Study type	Interventional
Source	United BioPharma
Contact
Status	Completed
Phase	Phase 1
Start date	December 2015
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01682109` - Palatability Testing of a New Paediatric Formulation of Valacyclovir	Phase 4
Completed	`NCT04713423` - Oral and Perioral Herpes Simplex Virus Infection Type I in a Five-month-old Infant: A Case Report
Completed	`NCT04560790` - Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis	N/A
Withdrawn	`NCT04294030` - NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2
Completed	`NCT05226949` - Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection
Completed	`NCT01689285` - Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir	Phase 1
Terminated	`NCT04081480` - Pharmacokinetics of Valacyclovir Oral Solution in Children	N/A